Gavi^® Automated Vitrification

Ideal Vitrification Environment

Gavi^_® helps you achieve optimal vitrification conditions in a different way¹². It vitrifies oocytes, cleavage and blastocyst stage embryos with an automated, standardised, controlled protocol allowing vitrification to happen the same way every time¹².
 
Oocytes/embryos are held in the Gavi^_® pod, key to the systems success the specially designed device also acts as the container for the oocytes/embryos in LN₂ storage. Gavi^_® can vitrify 8 oocytes and cleavage stage embryos simultaneously (2 per pod) and 4 blastocysts simultaneously (1 per pod) allowing the embryologist to take control of other duties while vitrification is being performed. Gavi^_® helps you with:

• Automated solution dispensing: A robotic liquid-handling unit dispenses the necessary solutions with a precision difficult to achieve by hand, and eliminating the need to manually move embryos between fluids³.
• Gavi^_® Pod design: Designed to secure embryos in place during fluid exchange and liquid nitrogen (LN₂) storage³, and to allow for fast cooling and warming rates.
• Control of exposure: The exposure timing to cryoprotectant solutions is carefully controlled to avoid toxic over-exposure³.
• Temperature control: sensors indicate that Gavi^_® is outside the recommended normal operational temperature range and if the heating module in Gavi^_® is outside of its acceptable temperature range¹².
• Reduces the risk of cross-contamination: After equilibration, the Pod is automatically heat-sealed so it can be placed directly into LN₂¹².

Gavi^_® Clinical Outcomes: The proof is in the results

At Genea, our manual vitrification outcomes were proven, data published in 2014 showed our single embryo transfer of vitrified-warmed blastocysts had equivalent live-birth rates and improved neonatal outcomes compared with fresh transfers².  Gavi_^® needed to be as good as our current system – and it was.

The following clinical data was obtained from the Genea clinic Gavi^_® implementation, it demonstrates that Gavi^_® delivers comparable clinical outcomes of blastocysts vitrified using the Gavi^_® system compared to Cyrotop system including, embryo survival and clinical pregnancy^3,9 The results continue for Gavi^_®, it has been highlighted at conferences since its launch at ESHRE London 2013. ASPIRE⁵ (Brisbane, 2014), ALPHA⁶ (Antalya, 2014) and data from using Gavi^_® clinically for oocyte vitrification was presented at ASRM 2017 (O-136)⁷.

Easy to use regardless of experience

Any implementation period gives an opportunity to analyse data and so we looked back. It became obvious how easy Gavi^_® was to learn and how quickly embryologists were able to achieve benchmark results compared to the manual method⁸.

When analysing the early stage implementation data for the two techniques in Genea clinics we found using Gavi^_® there was a reduction in the variability of results between embryologists and the period between basic vitrification competency to aspirational competency was reduced⁸.

What about storage?

Any new approach needs to be adaptable, Gavi^_® pods are securely stored on cassettes in specially designed single or double level liquid nitrogen Gavi^_® Storage Dividers¹². The dividers come in square or round configurations to fit easily into your existing storage vessels.

Gavi^_® Technology

• Pod with microfluidic dynamics that locates the embryo to allow automated fluid exchange
• Thin pod walls to ensure fast vitrification and warming rates
• Automated sealing to ensure pod is “fully closed” to eliminate risk of LN₂ contamination
• Gavi^_® has been recognised internationally and awarded Gold in the Medical Design Excellence Awards in New York in 2017.
• Gavi^_® has been awarded the Australian Good Design Award in the product design category in 2017.